A Pilot Study of Whether the Cold-Heat Syndrome Type is Associated with Treatment Response and Immune Status in Patients with Non-Small Cell Lung Cancer
Table 1
Demographic and clinical characteristics of 20 patients with non-cold or cold type.
Total (n = 20)
Adenocarcinoma (n = 14)
Non-cold (n = 11)
Cold (n = 9)
value
Non-cold (n = 7)
Cold (n = 7)
value
Age (year)
61.4 ± 12.1
61.1 ± 8.9
0.959
58.1 ± 13.2
59.3 ± 7.5
0.846
Sex
—
—
0.148
—
—
0.193
Female
0 (0.0%)
3 (33.3%)
0 (0.0%)
3 (42.9%)
Male
11 (100.0%)
6 (66.7%)
7 (100.0%)
4 (57.1%)
Smoking status
—
—
0.141
—
—
0.214
Current
8 (72.7%)
3 (33.3%)
5 (71.4%)
2 (28.6%)
Ex-smoker
2 (18.2%)
2 (22.2%)
1 (14.3%)
1 (14.3%)
Nonsmoker
1 (9.1%)
4 (44.4%)
1 (14.3%)
4 (57.1%)
Histologic type
—
—
0.844
—
—
Adenocarcinoma
7 (63.6%)
7 (77.8%)
7 (100.0%)
7 (100.0%)
Squamous
4 (36.4%)
2 (22.2%)
—
—
Drug
—
—
0.047
—
—
0.091
Pembrolizumab
4 (36.4%)
2 (22.2%)
4 (57.1%)
1 (14.3%)
Nivolumab
4 (36.4%)
0 (0.0%)
1 (14.3%)
0 (0.0%)
Atezolizumab
3 (27.3%)
7 (77.8%)
2 (28.6%)
6 (85.7%)
Line of therapy
—
—
0.059
—
—
0.013
2nd line therapy
9 (81.8%)
2 (22.2%)
6 (85.7%)
0 (0.0%)
3rd line therapy
1 (9.1%)
2 (22.2%)
0 (0.0%)
2 (28.6%)
4th line therapy
1 (9.1%)
4 (44.4%)
1 (14.3%)
4 (57.1%)
7th line therapy
0 (0.0%)
1 (11.1%)
0 (0.0%)
1 (14.3%)
No. of cyclea
7.0 ± 5.7
3.3 ± 1.1
0.110
7.0 ± 4.3
3.0 ± 1.2
0.106
Ongoing
3 (27.3%)
2 (22.2%)
2 (28.6%)
2 (28.6%)
Clinical response
—
—
0.668
—
—
0.549
Partial response
3 (27.3%)
1 (11.1%)
2 (28.6%)
1 (14.3%)
Stable disease
4 (36.4%)
4 (44.4%)
3 (42.9%)
2 (28.6%)
Progressive disease
4 (36.4%)
4 (44.4%)
2 (28.6%)
4 (57.1%)
PFS (day)a
102.0 (43.0; 172.5)
44.0 (42.0; 76.0)
0.332
130.0 (74.0; 166.0)
43.0 (42.0; 45.0)
0.036
PD-L1 expressionb
—
—
0.050
—
—
0.110
Negative
1 (9.1%)
4 (50.0%)
1 (14.3%)
4 (57.1%)
>0%, ≤50%
3 (27.3%)
3 (37.5%)
1 (14.3%)
1 (14.3%)
>50%
7 (63.6%)
1 (12.5%)
5 (71.4%)
1 (14.3%)
EGFR mutation
—
—
0.115
—
—
0.193
Positive
0 (0.0%)
3 (33.3%)
0 (0.0%)
3 (42.9%)
Negative
7 (63.6%)
4 (44.4%)
7 (100.0%)
4 (57.1%)
Not done
4 (36.4%)
2 (22.2%)
—
—
ALK mutation
—
—
0.621
—
—
0.368
Positive
1 (9.1%)
0 (0.0%)
1 (14.3%)
0 (0.0%)
Negative
6 (54.5%)
6 (66.7%)
6 (85.7%)
6 (85.7%)
Not done
4 (36.4%)
3 (33.3%)
0 (0.0%)
1 (14.3%)
KRAS mutation
—
—
0.638
—
—
0.247
Positive
2 (18.2%)
1 (11.1%)
2 (28.6%)
1 (14.3%)
Negative
4 (36.4%)
2 (22.2%)
4 (57.1%)
2 (28.6%)
Not done
5 (45.5%)
6 (66.7%)
1 (14.3%)
4 (57.1%)
aData of 5 patients whose ICI treatment was not finished (ongoing) were excluded. bMissing data (not done) of one patient were excluded for the analysis.
